NeuroVive proposes a rights issue of MSEK 74 and accelerates the clinical development of KL1333
(WorldNews Finland)

NeuroVive proposes a rights issue of MSEK 74 and accelerates the clinical development of KL1333 Lund, Sweden, 19 February 2020, NeuroVive Pharmaceutical AB (Nasdaq Stockholm) today announced that the Board of Directors of NeuroVive Pharmaceutical AB (publ) (`NeuroVive` or the `Company`) has resolved, subject to approval by the Extraordinary General Meeting, on a new share issue with preferential rights for the Company`s existing shareholders (the `Rights issue`) in order to ensure that the Company has financial resources for its prioritized primary mitochondrial disease (PMD) programs, primarily the continued clinical development of KL1333. The Board`s resolution on the Rights issue is...